title: Cerebrospinal fluid angiotensin-converting enzyme (ACE) correlates with length of illness in schizophrenia.
abstract: The aim of the study was to evaluate a possible progression with time of cerebrospinal fluid (CSF) angiotensin-converting enzyme (ACE) levels in treated schizophrenia patients. CSF ACE was determined in duplicate by a sensitive inhibitor-binding assay (IBA) from morning CSF samples of 56 acute and chronic in-patients with schizophrenic psychoses diagnosed according to DSM-IV. CSF ACE correlated significantly with length of schizophrenic psychosis (r=0.39, p=0.003). There was also a positive significant correlation between CSF ACE and duration of current psychotic episode (r=0.39, p=0.003) as well as duration of current hospitalization (r=0.66, p<0.001). These significances were maintained even when patients who were not treated with antipsychotics at the time of sampling were excluded. The correlations also remained significant when controlling for current neuroleptic dose in chlorpromazine equivalents. Serum ACE did not correlate with any clinical variable. No significant correlations between serum or CSF ACE and age, diagnostic subgroup, gender, serum ACE, CSF to serum albumin ratios, or neuroleptic dose in chlorpromazine equivalents were detected. The elevation of CSF ACE seemed to be confined to a subgroup of chronic patients with few positive symptoms. Elevated CSF ACE may reflect an increased solubilization of ACE from cell membranes in the central nervous system or constitute an increased expression of the ACE gene in response to some stimuli. This may be a function of treatment or a result of the deteriorating schizophrenic process.
authors.affiliation: Department of Psychiatry, University of Helsinki, Lappviksvägen, Finland. kristian.wahlbeck@huch.fi
authors.forename: K
authors.initials: K
authors.lastname: Wahlbeck
authors.forename: A
authors.initials: A
authors.lastname: Ahokas
authors.forename: H
authors.initials: H
authors.lastname: Nikkilä
authors.forename: K
authors.initials: K
authors.lastname: Miettinen
authors.forename: R
authors.initials: R
authors.lastname: Rimón
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000134:cerebrospinal fluid*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy / Q000201:enzymology
chemical_list: D014150:Antipsychotic Agents; D007703:Peptidyl-Dipeptidase A